Pfizer Inc (NYSE:PFE), based in NEW YORK, recently reported along with Bristol Myers Squibb Co (NYSE:BMY), that the Ministry of health, Labor and Welfare of Japan has approved ELIQUIS for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation or NVAF.
The medicine is a novel anticoagulant that has shown risk decreases against warfarin in three important outcomes of stroke, key bleeding and all-cause death.
ELIQUIS, a trial oral anticoagulant, was discovered by Bristol-Myers Squibb and in 2007, both corporation entered into a globally collaboration to develop and commercialize the medicine.
Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. GlaxoSmithKline plc (ADR) (NYSE:GSK) fell -0.57% to settle at $43.23, Mylan Inc. (NASDAQ:MYL) moved down -1.57% to end at $26.92 while Bristol Myers Squibb Co. (NYSE:BMY) dropped -0.75% to finish at $31.90 on Friday.
Pfizer Inc. (NYSE:PFE) on Dec 28, 2012 decreased -0.99% to the closing price of $24.89. The overall volume in the last trading session was 21.61 million shares. Its fifty two weeks range was $20.75 – $26.09. The total market capitalization remained at $183.25 billion.
PFE is ahead of its 52-week low with 23.38% and lagging behind from its 52-week high price with -3.75%. PFE’s last month’s stock price volatility remained 1.31%. In its share capital PFE has 7.36 billion outstanding shares, among them 7.36 billion shares have been floated in market exchange. PFE’s stock’s institutional ownership remained 73.03% while insider ownership included 0.01%.
The stock price of PFE is moving down from its 20 days moving average with -1.68% and remote negative from 50 days moving average with -0.04%. PFE’s current year’s earnings per share experienced an addition with 9.08% while its current quarter performance remained at 9.08%. Company’s beta coefficient included 0.71. Beta factors measure the amount of market risk associated with market trade.
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL